Education
About Us
Working with TipRanks
Follow Us
UBS Oncology Impact Fund L.P. Insider Profile
4 Followers
UBS Oncology Impact Fund L.P., Ten Percent Owner at Harpoon Therapeutics, holds 0.00 shares in TCR2 Therapeutics (Ticker: TCRR), holds 7.65M shares in Cullinan Management (Ticker: CGEM), holds 2.38M shares in Oncorus (Ticker: ONCR).
UBS Oncology Impact Fund L.P. Harpoon Therapeutics (HARP)Ten Percent Owner
Harpoon Therapeutics (HARP)
Ten Percent Owner
Ranked #82,561 out of 100,956 Corporate Insiders
Profitable Transactions
1 out of 4 Profitable Transactions
Average Return
-27.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of UBS Oncology Impact Fund L.P.'s holdings
Insider Roles
Ten Percent Owner
Roles that UBS Oncology Impact Fund L.P. holds in companies
Most Profitable Insider Trade
Stock:
Harpoon Therapeutics
(HARP)
(HARP)
Rating:Informative Buy
Date:Feb 14, 2019 - Feb 14, 2020
Return:+4.90%
The most profitable trade made by UBS Oncology Impact Fund L.P.
UBS Oncology Impact Fund L.P.'s Trading History
Harpoon Therapeutics
Feb 14, 2019
―
Informative Buy
3.50M
$89.70M
TCR2 Therapeutics
Jun 05, 2023
―
Uninformative Sell
―
$0.00
Oncorus
Oct 08, 2020
―
Uninformative Buy
―
$299.51K
Cullinan Management
Sep 20, 2021
Ten Percent Owner
Uninformative Sell
90.78K
$66.62M
List of latest transactions for each holding click on a transaction to see UBS Oncology Impact Fund L.P.'s performance on stock
You May Also Like
UBS Oncology Impact Fund L.P. insider profile FAQ
What is the percentage of profitable transactions made by UBS Oncology Impact Fund L.P.?
The percentage of profitable transactions made by UBS Oncology Impact Fund L.P. is 25%.
What is the average return per transaction made by UBS Oncology Impact Fund L.P.?
The average return per transaction made by UBS Oncology Impact Fund L.P. is -27.10%.
What stocks does UBS Oncology Impact Fund L.P. hold?
UBS Oncology Impact Fund L.P. holds: HARP, TCRR, ONCR, CGEM stocks.
What was UBS Oncology Impact Fund L.P.’s latest transaction?
UBS Oncology Impact Fund L.P. latest transaction was an Uninformative Sell of ―.
What was UBS Oncology Impact Fund L.P.'s most profitable transaction?
UBS Oncology Impact Fund L.P.’s most profitable transaction was an Informative Buy of HARP stock on February 14, 2019. The return on the trade was 4.90%.
What is UBS Oncology Impact Fund L.P.'s role in Harpoon Therapeutics?
UBS Oncology Impact Fund L.P.'s role in Harpoon Therapeutics is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.